Online citations, reference lists, and bibliographies.
← Back to Search

SU6668, A Multiple Tyrosine Kinase Inhibitor, Inhibits Progression Of Human Malignant Pleural Mesothelioma In An Orthotopic Model

Trung The Van, M. Hanibuchi, Hisatsugu Goto, Takuya Kuramoto, Sawaka Yukishige, S. Kakiuchi, S. Sato, S. Sakaguchi, Le Tan Dat, Y. Nishioka, S. Akiyama, S. Sone
Published 2012 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background and objective:  Malignant pleural mesothelioma (MPM) is an aggressive neoplasm of the mesothelium with high chemotherapeutic resistance. In this study, the preclinical therapeutic activity of the multiple tyrosine kinase inhibitor, SU6668, against MPM was examined.
This paper references
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
A. Laird (2000)
10.1002/ijc.20751
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU‐68)
S. Machida (2005)
10.1007/s00280-010-1503-x
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
Trung The Van (2010)
10.1038/ncponc0839
Malignant pleural mesothelioma: current concepts in treatment
A. Tsiouris (2007)
10.1016/J.LUNGCAN.2005.03.012
Molecular prognostic markers in malignant mesothelioma.
Priya Kumar (2005)
10.1007/s10637-011-9683-8
A phase I pharmacokinetic study of TSU-68 (a multiple tyrosine kinase inhibitor of VEGFR-2, FGF and PDFG) in combination with S-1 and oxaliplatin in metastatic colorectal cancer patients previously treated with chemotherapy
S. Shin (2011)
10.1378/CHEST.128.5.3382
Prognostic significance of vascular endothelial growth factor, tumor necrosis, and mitotic activity index in malignant pleural mesothelioma.
F. Demirag (2005)
10.1634/THEONCOLOGIST.9-5-482
FDA drug approval summaries: pemetrexed (Alimta).
M. Hazarika (2004)
A multicenter phase II study of pemetrexed, cisplatin, and bevacizumab in patients with advanced malignant mesothelioma
J Dowell (2009)
10.1158/1078-0432.CCR-07-0501
The Therapeutic Efficacy of Anti–Vascular Endothelial Growth Factor Antibody, Bevacizumab, and Pemetrexed against Orthotopically Implanted Human Pleural Mesothelioma Cells in Severe Combined Immunodeficient Mice
Q. Li (2007)
10.1002/(SICI)1096-9896(199706)182:2<211::AID-PATH834>3.0.CO;2-D
EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMA
S. Kumar-Singh (1997)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1186/1471-2407-7-49
Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo
F. Klenke (2006)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/j.ejca.2009.02.022
Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines.
J. Nutt (2009)
10.1054/bjoc.2001.1997
Angiogenesis is an independent prognostic factor in malignant mesothelioma
J. Edwards (2001)
10.1093/carcin/bgp097
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
K. Kawaguchi (2009)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
10.3892/OR.14.3.677
TSU-68 (SU6668) inhibits local tumor growth and liver metastasis of human colon cancer xenografts via anti-angiogenesis.
K. Yorozuya (2005)
10.1002/AJIM.20246
Estimation of future mortality from pleural malignant mesothelioma in Japan based on an age-cohort model.
Takehiko Murayama (2006)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1097/00000658-197203000-00014
Anti‐Angiogenesis: New Concept for Therapy of Solid Tumors
J. Folkman (1972)
10.1007/s10147-003-0342-8
Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy
Y. Sato (2002)
10.1097/01.JTO.0000283221.63767.BA
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
10.1083/JCB.141.7.1659
Fibroblast Growth Factor-2 (FGF-2) Induces Vascular Endothelial Growth Factor (VEGF) Expression in the Endothelial Cells of Forming Capillaries: An Autocrine Mechanism Contributing to Angiogenesis
G. Seghezzi (1998)
10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0
Angiogenic cytokines in mesothelioma: a study of VEGF, FGF‐1 and ‐2, and TGF β expression
S. Kumar-Singh (1999)
10.1016/0022-1759(84)90190-X
Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.
L. Green (1984)
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.
A. Garofalo (2003)
Angiogenesis: an organizing principle for drug discovery?
J. Folkman (2007)
10.1158/1078-0432.CCR-09-1980
E7080, a Multi–Tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles
K. Ikuta (2009)
10.1007/s00423-007-0150-0
Angiogenesis in cancer: molecular mechanisms, clinical impact
M. Eichhorn (2007)
10.1093/JNCI/88.16.1146
Platelet-derived endothelial cell growth factor in human colon cancer angiogenesis: role of infiltrating cells.
Y. Takahashi (1996)



This paper is referenced by
The role of inflammasomes in asbestos-induced mesothelial to fibroblastic transition
Joyce K. Thompson (2017)
Growth factor-induced epithelioid-sarcomatoid transition in malignant pleural mesothelioma cells?
Christina Wagner (2015)
miR-381-3p suppresses the proliferation of oral squamous cell carcinoma cells by directly targeting FGFR2.
X. Yang (2017)
10.1007/978-3-030-16884-1_5
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Elisabeth Digifico (2019)
10.1111/resp.12048
Year in review 2012: Lung cancer, respiratory infections, tuberculosis, pleural diseases, bronchoscopic intervention and imaging
J. M. Porcel (2013)
10.1186/1475-2867-13-88
SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression
L. Wang (2013)
10.4172/1948-5956.1000413
Fibroblast Growth Factors and their Emerging Cancer-Related Aspects
A. Khalid (2016)
10.1039/C4MD00560K
Novel pyrrole derivatives as selective CHK1 inhibitors: design, regioselective synthesis and molecular modeling
Taha M. A. Eldebss (2015)
10.1016/S1470-2045(13)70125-6
Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study.
W. Buikhuisen (2013)
10.1007/s12032-016-0758-4
Multi-kinase inhibitors, AURKs and cancer
J. Cicenas (2016)
10.18632/ONCOTARGET.1126
Identification of pregnancy-associated plasma protein A as a migration-promoting gene in malignant pleural mesothelioma cells: a potential therapeutic target
J. Huang (2013)
10.1007/978-3-030-16884-1_6
Preclinical Models in Mesothelioma
Ilaria Fuso Nerini (2019)
10.1007/978-3-319-53560-9_7
Asbestos-Induced Inflammation in Malignant Mesothelioma and Other Lung Diseases
Joyce K. Thompson (2017)
10.2147/OTT.S104556
Metadherin regulates epithelial–mesenchymal transition in carcinoma
Z. Wang (2016)
10.1007/978-3-319-53560-9_15
Standard Chemotherapy Options and Clinical Trials of Novel Agents for Mesothelioma
M. Zauderer (2017)
10.1186/1479-5876-11-106
Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer
S. Weibel (2012)
Semantic Scholar Logo Some data provided by SemanticScholar